Erika M. Moore, MD
Assistant Professor of Pathology



Dr. Erika M. Moore is a member of the Division of Hematopathology.







Office Location:
Hill Building 3rd Floor, Rm #357
3477 Euler Way
Pittsburgh, PA 15213
Contact Information:
Office Telephone: 412-647-4162
Fax: 412-647-4008
Email: erikamoore@upmc.edu

Education

  • MD - University of Pennsylvania School of Medicine, 2010
  • Residency - Hospital of the University of Pennsylvania, 2010-2014
  • Fellowship - Hematopathology, University of Pittsburgh Medical Center, 2014-2015

Research Interests

Dr. Moore's research interests include further characterization of hematopoietic neoplasms using immunohistochemistry, flow cytometry, and genetic studies, as well as integration of clinical prognostic and therapeutic information. She is particularly interested in B-cell lymphomas but also studies myeloid neoplasms. Recent and ongoing projects include evaluation of the flow cytometric and genetic characteristics of myelodysplastic/myeloproliferative neoplasms, unclassifiable, review of the pathologic and clinical characteristics of patients who have significant bone marrow involvement by a chronic lymphocytic leukemia/small lymphocytic lymphoma-like B-cell proliferation but who do not meet diagnostic criteria for lymphoma, and assessment of MEF2B immunohistochemistry in mantle cell lymphomas.

Selected Publications

  1. Moore EM, Swerdlow SH, Gibson SE. Comparison of Myocyte Enhancer Factor 2B Versus Other Germinal Center-associated Antigens in the Differential Diagnosis of B-Cell Non-Hodgkin Lymphomas. Am J Surg Pathol. 2018 Mar;42(3):342-350.
  2. Tomlinson B, Raess PW, Beck RC, Moore EM. Erythroblastic Sarcoma With Rare PDGFRA Rearrangement Responding to Tyrosine Kinase Inhibitor Therapy. Br J Haematol. 2020 Mar;188(6):e98-e100.
  3. Jajosky A, Havens NP, Sadri N, Oduro KA, Moore EM, Beck RC, Meyerson HJ. Clinical Utility of Targeted Next-Generation Sequencing in the Evaluation of LowGrade Lymphoproliferative Disorders. Am J Clin Pathol, 2021 Mar; Online ahead of print.
  4. Li Y, Beck RC, Moore EM. Pathogenic Mutations and Atypical Flow Cytometric Findings Characterize the Majority of Unclassifiable Myelodysplastic/Myeloproliferative Neoplasms. Am J Clin Pathol. 2021 Apr 20; Online ahead of print.
  5. Jajosky A, Sadri N, Meyerson H, Oduro K, Kelkar A,; Fitzgerald B, Tomlinson B, Moore EM, Beck RC. Clonal cytopenia of undetermined significance (CCUS) with dysplasia is enriched for MDS-type molecular findings compared to CCUS without dysplasia. Eur J Haematol. 2021 April;106(4):500-507.
  6. Wang XJ, Moore EM, Swerdlow SH, Aggarwal N. Light Chain Restricted Plasmacytoid Cells in Hyperplastic Germinal Centers: A Clinicopathologic Investigation. Am J Clin Pathol. Accepted Jan 2021
  7. Bhavsar S, Liu Y, Gibson, SE, Moore EM, Swerdlow SH. Mutational landscape of TdT+ large B-cell lymphomas supports their distinction from B-lymphoblastic neoplasms, a multiparameter study of a rare and aggressive entity. Am J Surg Pathol. Accepted May 2021.